What Aircast Treats: Main Uses and Benefits

Aircast (Montelukast) is commonly used to provide supportive relief by helping to manage symptoms related to inflammatory or irritative states in the respiratory and upper airways. This targeted approach is used in areas where additional symptomatic support is needed, and may assist with maintaining functional stability.

The medication may be part of symptomatic management for chronic asthma, seasonal and perennial allergic rhinitis, and exercise-induced bronchoconstriction (EIB). It is relevant for easing the symptomatic manifestations of chronic conditions and helps address symptom clusters that may become intense or disruptive.

---

Therapeutic Domains

Aircast is applied across domains where additional symptomatic support is needed for chronic conditions. It is relevant for managing symptoms that become more disruptive during flare-ups, such as recurrent wheezing, chronic coughing, and chest tightness. This supports the patient during difficult episodes and contributes to easing the overall symptom load.

The medication is also commonly used across conditions presenting with acute episodes of allergic rhinitis and is applied in addressing the symptoms associated with EIB. It helps manage symptoms that interfere with daily functioning, like nasal congestion and exercise-related breathing difficulties. This assists with maintaining functional stability during both symptomatic periods and physical activity.

---

Quick Fact: Supportive Management for Airway and Nasal Symptoms

A key role is commonly used to help with persistent respiratory symptoms (wheezing, coughing) and acute nasal symptoms (sneezing, runny nose). This supports general well-being during symptomatic phases.

Aircast (Montelukast sodium) eligibility is strictly defined by regulatory documents based on age, existing health conditions, and hypersensitivity status. The most definitive restriction is its contraindication for any patient with a known allergy or hypersensitivity to Montelukast or any component of the formulation.

Age-Based Eligibility

The medicine is authorized for various age groups depending on the specific condition it addresses. For chronic asthma, use is established for patients mathbf12 months and older. For Seasonal Allergic Rhinitis, the minimum age is mathbf2 years, and for Perennial Allergic Rhinitis, it is mathbf6 months. Use for preventing Exercise-Induced Bronchoconstriction (EIB) is established for patients mathbf6 years and older. Safety and effectiveness are not established for populations below these age thresholds.

Conditional Use and Restrictions

Aircast is not indicated for the treatment of acute asthma attacks. For Allergic Rhinitis, its use is officially reserved for patients who have an inadequate response or intolerance to alternative treatments. For organ function, no dosage adjustment is required for patients with renal impairment or mild to moderate hepatic impairment; however, no data are available for patients with severe hepatic impairment. Regarding pregnancy and lactation, available data have not established a drug-associated risk, and no special precautions are generally required.

Interactions with other medicines and products

Aircast (Montelukast) interacts with other medicinal products through officially documented pharmacokinetic changes and specific administration-related restrictions, as detailed in regulatory labeling.

Metabolic and Exposure-Altering Interactions

Montelukast is metabolized by the cytochrome P450 (CYP) enzyme system, primarily involving CYP2C8, CYP3A4, and CYP2C9. This metabolic pathway is the basis for several documented pharmacokinetic interactions. The co-administration of the potent enzyme inducer Rifampin results in a significant reduction, approximately 40%, in the systemic exposure (Area Under the Curve, or AUC) of Montelukast. Conversely, co-administration with Gemfibrozil, an inhibitor of the CYP2C8 enzyme, is documented to cause a substantial increase, resulting in a 4.3-fold higher AUC for Montelukast. Other enzyme-inducing agents such as Phenobarbital, Phenytoin, and Carbamazepine are also noted to potentially reduce the concentration of the medicine.

Administration and Formulation Restrictions

Regulatory documents impose several key restrictions. Aircast must not be abruptly substituted for either oral or inhaled corticosteroids. Additionally, patients with documented aspirin sensitivity must maintain the avoidance of co-administering the medicine with aspirin or other Non-Steroidal Anti-Inflammatory Drugs (NSAIDs). The medicine may be taken without regard to food. A formulation-specific restriction applies to the chewable tablets: they are restricted in patients with Phenylketonuria (PKU) because the formulation contains aspartame, which is a source of phenylalanine.

How Aircast Works

Aircast's mechanism is defined by its highly specific action within the inflammatory signaling cascade, engaging the CysLT₁ receptor, which modulates key physiological processes in the airways.

---

Specific Blockade of the CysLT₁ Receptor

The core action of the medicine involves selective and competitive antagonism of the Cysteinyl Leukotriene Receptor Type 1 (CysLT₁). This mechanism blocks the activation signal that originates from the potent inflammatory mediators cysteinyl leukotrienes (LTD4), which are released from mast cells and eosinophils. This antagonism intervenes in leukotriene signaling and modifies its downstream effects on the respiratory system.

---

️ Modulation of Airway Muscle Tone and Vascular Function

By suppressing the CysLT₁ signal, the drug's mechanism leads to two primary physiological consequences: inhibition of smooth muscle contraction and a reduction in microvascular leakage. This cascade results in a state of reduced leukotriene-mediated reactivity within the peripheral pathways of the respiratory tract. The mechanism operates by competitive blockade and sustained pathway inhibition rather than immediate, rapid-acting functional activation.

How to use Aircast

Aircast (Montelukast) is administered exclusively through the oral route. The standard adult dose for individuals 15 years and older is a single 10 mg dose per day. This is the maximum dose permitted within any 24-hour period.

The administration schedule is determined by the condition being addressed. For the chronic treatment of asthma, the medicine is specified to be taken once daily in the evening. Tablets and chewable tablets may be taken with or without food. For the prevention of exercise-induced events, a single 10 mg dose should be taken at least 2 hours before the activity; however, patients already on a daily dose must not take an additional dose for this purpose.

Special administration conditions apply to the 4 mg oral granules. These must be administered quickly, within 15 minutes of opening the packet. The granules may be mixed with specific soft foods (e.g., applesauce) or 5 mL of breast milk or baby formula, but must not be diluted with water or other general liquids. Regarding a missed dose, the procedure is to skip the missed dose and resume the regular schedule, without taking two doses at once to compensate. The treatment for chronic conditions is intended for continuous, long-term maintenance.

Research Evidence / Overview of Studies for Aircast (Montelukast)

---

Evidence Overview: Studies for Chronic Asthma Management

Research examining Montelukast for chronic asthma management primarily relied on Randomized Controlled Trials (RCTs) and systematic reviews, which compared it against placebo or other maintenance therapies. These studies explored how symptoms change over time and focused on outcomes related to systemic or functional imbalance. Research monitored physiological strain by measuring pulmonary function markers, like the volume of air expelled in one second ( FEV1), and also examined patient-reported outcomes describing perceived discomfort. Trials monitored populations involving children as young as 12 months, adolescents, and adults.

Studies monitored patient experiences during periods of increased symptom activity. Research highlights changes measured during the study period, with findings observing changes in lung function measurements and in the reported frequency of rescue inhaler use in some observed groups compared to placebo. Evidence contributes to understanding symptom patterns, but comparative evidence against certain alternative maintenance therapies was mixed.

Evidence Overview: Studies for Exercise-Induced Bronchoconstriction (EIB)

Montelukast was evaluated in short-term placebo-controlled RCTs relevant in trials assessing short-term or episodic symptom patterns related to exercise-induced bronchoconstriction (EIB). These studies primarily monitored outcomes describing episodic or acute changes by measuring the maximum drop in FEV1 after a standardized exercise challenge.

Studies focusing on episodes where symptoms become more noticeable described measurements related to the typical drop in FEV1 observed after exercise in some studies. Findings describe group patterns showing that these measured changes occurred in some studies within hours after a single dose. The evidence is limited regarding the effects of using the medicine continuously every day for EIB management, as most research explored the impact of a single dose.

---

Research Gaps and Uncertainties

Montelukast was evaluated in populations including infants, children, and adults. However, limited data exist for children under 6 for the EIB indication, and the impact of the short follow-up durations in many pivotal studies is not fully established. Research highlights what is known — and what is still uncertain — concerning the long-term effects of daily use, especially when compared directly against alternative treatments over many years.

Key Studies & References

1. Montelukast in the treatment of allergic rhinitis: an evidence-based review
2. Public Assessment Report Scientific discussion Montelukast Amarox 10 mg, film‐coated tablets

Common questions about Aircast (FAQ)

---

Q: What is the meaning of the active ingredient Montelukast sodium?

A: Aircast is the trade name for the active ingredient Montelukast sodium. The official classification shows that this name refers to the specific chemical form, a sodium salt, of the synthetic compound Montelukast. This compound is classified as a Leukotriene Receptor Antagonist.

Q: Is Aircast a steroid?

A: No, Aircast is officially classified as a Leukotriene Receptor Antagonist (LTRA), not a steroid. Regulatory documents state that this medicine works by blocking specific inflammatory signals (leukotrienes) and must not be used as a substitute for oral or inhaled corticosteroids.

Q: What is the difference between Aircast and Zafirlukast or Pranlukast (other LTRAs)?

A: Aircast (Montelukast) belongs to the same class of medicines, Leukotriene Receptor Antagonists (LTRAs), as Zafirlukast and Pranlukast. The regulatory basis for their use and differences in things like specific warnings, dosing, and age indications are described in the individual official documents for each medicine.

Q: What is the minimum age a child can use Aircast for asthma?

A: According to official regulatory labeling, Aircast is authorized for the chronic, long-term treatment of asthma in patients mathbf12 months and older. Safety and effectiveness are not established by regulatory bodies for use in children below this specified age.

Q: Does Aircast need a dosage adjustment for older adults?

A: Official documentation indicates that no specific dosage adjustment for Aircast is typically required for older adult patients. This also applies to patients with mild to moderate impairment of kidney (renal) or liver (hepatic) function.

Q: Does Aircast have generic versions?

A: Yes. Following the patent expiration of the original brand-name product, the active ingredient, Montelukast sodium, has been approved by government authorities for marketing as a generic medication.

Q: What research exists on how Aircast affects lung function?

A: Research studies examined changes in pulmonary function markers, such as the volume of air expelled in one second ( FEV1). Research findings have described changes in these measurements and in the reported use of rescue inhalers in some study groups compared to placebo.

Q: What is the typical time frame for Aircast to start working for asthma control?

A: The medicine's active substance is rapidly absorbed into the bloodstream, reaching mean peak concentrations in approximately 2 to 4 hours. However, the medicine's official and intended role is for continuous, long-term maintenance and chronic control, not for immediate relief.

Q: Does Aircast cause liver problems (hepatitis)?

A: Official safety documentation lists hepatitis (liver injury) as a very rare adverse reaction. Other reports of liver function changes have been noted during post-marketing surveillance for this class of medicine.

Q: Does Aircast affect a person's ability to drive a vehicle or operate machinery?

A: Official information advises that the medicine can rarely cause side effects such as dizziness, somnolence (sleepiness), and hallucinations. Official guidance states that if a patient experiences these effects or any others that may impair concentration, they should avoid driving or operating machinery.

Q: Does Aircast interact with other medicines besides Rifampin and Gemfibrozil?

A: Yes, regulatory documents note that the metabolism of Aircast can be affected by other enzyme-inducing agents. These agents include mathbfPhenobarbital, mathbfPhenytoin, and mathbfCarbamazepine, which are associated with a potential reduction in the concentration of the medicine in the body.

Q: What happens if Aircast is taken for the prevention of exercise-induced events on the same day as the daily asthma dose?

A: Official administration instructions specify that patients already on a daily dose for chronic asthma must not take an additional dose for the prevention of exercise-induced events within the same 24-hour period. The medicine is not intended to be taken more than once daily.

Q: Is it safe to stop taking Aircast suddenly?

A: Regulatory authorities state that if a patient experiences new or worsening neuropsychiatric symptoms, the medicine’s discontinuation may be considered, and immediate medical attention is required. Official information also notes that abruptly stopping the medicine may be associated with a potential for worsening of asthma symptoms in some patients.

Q: What should I do if I think I am having a severe allergic reaction (like anaphylaxis) to Aircast?

A: Official safety information lists severe reactions, including anaphylaxis (a severe allergic reaction) and angioedema (swelling). Regulatory guidance emphasizes that in the event of such a reaction, immediate discontinuation of the medicine and seeking emergency medical attention are necessary actions.

Q: What is the best way to dispose of unused Aircast medication?

A: The recommended method for disposal of unused or expired medicine involves a local drug take-back program. If this option is not available, regulatory guidance describes a process where the medicine can be mixed with an undesirable substance (such as dirt or used coffee grounds), placed in a sealed container, and discarded in the household trash, while avoiding discharge into drains or water courses.

Storage and Disposal of Aircast (Montelukast Sodium)

The storage and disposal of Aircast formulations, including tablets and oral granules, must strictly follow regulatory requirements to maintain product stability and ensure safety.

---

Official Storage Conditions

Requirement	Specific Instruction
Temperature	Store at Controlled Room Temperature (20 C to 25 C / 68 F to 77 F).
Protection	Must be protected from both light and moisture.
Packaging	Keep in the original, tightly closed container.
Child Safety	Must be kept out of the sight and reach of children.

---

Handling and Disposal Rules

• Oral Granule Stability: Once oral granules are mixed with food or liquid, the entire dose must be administered within 15 minutes and cannot be stored for later use.
• Safe Disposal: Unused or expired medication should be disposed of safely, preferably through a drug take-back program.
• Environmental Caution: Disposal must avoid discharge into drains or water courses.